Filing summary
Entity and period: The supplied filing is Nuvilex, Inc.’s unaudited Form 10-Q for the quarter ended October 31, 2012, covering its fiscal second quarter and six-month year-to-date period. This does not match the requested company name, Pharmacyte Biotech, Inc.; verify that this is the intended filing.
Business context
Nuvilex described a strategic shift toward biotechnology and pharmaceutical development, centered on its June 2012 acquisition of Austrianova Singapore Private Limited (ASPL). Existing product sales continued at a small scale, while management said it directed limited funds toward maintaining the parent company and ASPL and completing the acquisition-related financing.
Financial results and liquidity
| Metric | Three months ended October 31, 2012 | Six months ended October 31, 2012 | Prior-year comparable period |
|---|---|---|---|
| Revenue | $6,287 | $12,913 | $19,844 and $39,606, respectively |
| Gross profit (loss) | $(3,333) | $3,293 | $13,808 and $17,895, respectively |
| Operating expenses | $345,463 | $890,875 | $417,539 and $1,074,224, respectively |
| Net loss | $(382,816) | $(893,333) | $(437,152) and $(1,123,170), respectively |
| Net cash used in operations | Not presented separately | $(169,880) | $(171,195) for six months |
- Six-month revenue fell about 67% year over year; the company attributed reduced sales and marketing activity partly to limited funds and its focus on ASPL.
- Six-month net loss narrowed by about $230,000, primarily as compensation and sales and marketing expenses declined. The quarter’s loss also narrowed, mainly due to lower compensation expense.
- At October 31, cash was $22,696, current assets were $1.287 million, and current liabilities were $3.498 million, producing negative working capital of $2.211 million. Total liabilities were $3.790 million; stockholders’ deficit was $2.054 million. The balance sheet also reported $580,000 of preferred stock outside stockholders’ equity.
- Six-month cash flows: $169,880 used in operations and $321,750 used for acquisition payments, offset by $498,603 provided by financing. Ending cash was $22,696.
- Current liabilities included $2.264 million of settlement obligations and $420,000 of loans payable; long-term related-party debt was $292,000. The filing also disclosed a past-due $20,000 note bearing 8% interest and a $400,000 licensing-fee obligation under negotiation for settlement.
Material changes, outlook, and risks
- ASPL acquisition shares and Nuvilex shares were held in escrow, subject to financing and other agreement requirements. The agreement required $2.5 million in future ASPL funding, targeted by December 31, 2012, with $60,000 monthly operating funding in the interim. The relationship was later extended through the first quarter of 2013.
- The company’s private placement sought to raise $3.5 million to $5 million. It reported $503,500 in placement proceeds during the period in the stockholders’ equity note and $443,500 in common-stock sale proceeds in the cash-flow statement; the filing does not explain this difference clearly. It reported another $60,000 received after October 31.
- Management and the filing cited substantial doubt about the company’s ability to continue as a going concern, given minimal revenue, accumulated deficit of $40.741 million, negative working capital, and dependence on further financing. Management warned that inability to raise capital or generate operating liquidity could materially harm the business.
- The Cornerstone Bank settlement involved a judgment of $1,975,889 as of May 16, 2012, accruing interest at 7.75%, with a two-year stay of execution subject to settlement terms. A property and 14,605,614 shares were pledged toward the obligation; neither had been sold as of the filing, and the related asset and liability remained on the balance sheet.
- Management stated that internal control over financial reporting was not effective at October 31, 2012 and identified material weaknesses, including incomplete accounting procedures, underused systems, and no board audit committee financial expert. Remediation was underway; management aimed for effective controls by April 30, 2013.
- The filing gave no quantified financial guidance. Management’s stated plans included addressing prior debt, funding and developing ASPL’s encapsulation technology, and pursuing product, licensing, and joint-venture opportunities. Forward-looking plans were subject to financing, regulatory, commercial, competition, and execution risks.
Investor verification points
- Confirm the issuer identity: the filing is for Nuvilex, Inc., not Pharmacyte Biotech, Inc.
- Verify ASPL acquisition status, escrow release conditions, the $2.5 million funding obligation, and monthly funding requirements.
- Reconcile the private-placement proceeds reported in the equity note and cash-flow statement, and verify subsequent financing received.
- Track the Cornerstone settlement, including disposition of the property and pledged shares and the remaining obligation.
- Assess near-term liquidity, related-party funding, debt settlement progress, and the company’s ability to continue as a going concern.
- Review progress in remediating the disclosed material weaknesses and any subsequent control assessment.